TW446704B - Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia - Google Patents

Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia Download PDF

Info

Publication number
TW446704B
TW446704B TW088107606A TW88107606A TW446704B TW 446704 B TW446704 B TW 446704B TW 088107606 A TW088107606 A TW 088107606A TW 88107606 A TW88107606 A TW 88107606A TW 446704 B TW446704 B TW 446704B
Authority
TW
Taiwan
Prior art keywords
dimethyl
compound
hydrogen
alkyl
pharmaceutically acceptable
Prior art date
Application number
TW088107606A
Other languages
English (en)
Chinese (zh)
Inventor
Paul Jeffrey Dollings
Arlene Joan Dietrich
Jay Edward Wrobel
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of TW446704B publication Critical patent/TW446704B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW088107606A 1998-05-12 1999-05-11 Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia TW446704B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7644698A 1998-05-12 1998-05-12

Publications (1)

Publication Number Publication Date
TW446704B true TW446704B (en) 2001-07-21

Family

ID=22132072

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088107606A TW446704B (en) 1998-05-12 1999-05-11 Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia

Country Status (8)

Country Link
EP (1) EP1077968A1 (fr)
JP (1) JP2002514639A (fr)
CN (1) CN1308625A (fr)
AR (1) AR019842A1 (fr)
AU (1) AU3791699A (fr)
CA (1) CA2330555A1 (fr)
TW (1) TW446704B (fr)
WO (1) WO1999058522A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000018I1 (de) 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
AU2002349705A1 (en) 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
CN100334088C (zh) * 2003-05-15 2007-08-29 霍夫曼-拉罗奇有限公司 作为蛋白质酪氨酸磷酸酶抑制剂的二氨基吡咯并喹唑啉化合物
US7226915B2 (en) 2003-05-15 2007-06-05 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
CN102935081B (zh) 2005-09-14 2015-03-04 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (fr) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
EP2328910B1 (fr) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
ES2445917T3 (es) 2010-02-03 2014-03-06 Takeda Pharmaceutical Company Limited Inhibidores de quinasa 1 reguladora de la señal de apoptosis
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014057522A1 (fr) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions et procédés de traitement de la stéatohépatite non alcoolique
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
EP2968439A2 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
SG11201507288UA (en) 2013-03-15 2015-10-29 Mochida Pharm Co Ltd Compositions and methods for treating non-alcoholic steatohepatitis
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
CN106749169B (zh) * 2016-11-07 2020-04-21 浙江工业大学 一种Ertiprotafib的手性制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1129443A (zh) * 1993-06-14 1996-08-21 美国辉瑞有限公司 仲胺用作治糖尿病和治肥胖病药物
US5747527A (en) * 1995-06-06 1998-05-05 Shaman Pharmaceuticals, Inc. Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
JPH11512095A (ja) * 1995-08-28 1999-10-19 アメリカン・ホーム・プロダクツ・コーポレイション アルドース還元酵素阻害薬および抗高血糖症薬としてのフェノキシ酢酸

Also Published As

Publication number Publication date
CA2330555A1 (fr) 1999-11-18
JP2002514639A (ja) 2002-05-21
WO1999058522A1 (fr) 1999-11-18
CN1308625A (zh) 2001-08-15
EP1077968A1 (fr) 2001-02-28
AU3791699A (en) 1999-11-29
AR019842A1 (es) 2002-03-20

Similar Documents

Publication Publication Date Title
TW446704B (en) Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia
JP4482513B2 (ja) Ｎ２−（置換アリールメチル）−３−（置換フェニル）インダゾールおよびこれを含む抗血管形成剤
JP5244091B2 (ja) Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
RU2515968C2 (ru) 5-членное гетероциклическое соединение и его применение для лекарственных целей
AU2013366898B2 (en) Halogen-substituted heterocyclic compound
US20120238588A1 (en) 1H-Pyrrolo[2,3-B]Pyridines
CN101133037B (zh) 六元杂环化合物及其用途
TWI304805B (en) New retinoids for the treatment of emphysema
WO2007015744A1 (fr) Composés thiényl bi-substitués et leur utilisation en tant que produits pharmaceutiques
JP2009516694A (ja) 化合物
TW200400183A (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
JP2009516746A (ja) 化合物
JP2009516695A (ja) 化合物
TW201010977A (en) Amide compound
MXPA06001739A (es) Derivado de acido arilalcanoico substituido y uso del mismo.
TW201028389A (en) GPR120 receptor agonists and uses thereof
IL31246A (en) Phenylethananolamine compounds, their preparations and veterinary medicinal products containing them
CA1229047A (fr) Derives de benzothiophene utilises comme agents antiasthmatiques
CN104109115B (zh) 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
RU2661878C2 (ru) Композиции для лечения гипертензии и/или фиброза
KR970011580B1 (ko) 항알레르기 활성을 갖는 신규의 벤조티오펜
JP2001512113A (ja) 抗腫瘍及び抗転移剤としてのｏ−置換ヒドロキシクマラノン誘導体
WO1999027965A1 (fr) Agents anti-hyperlipemiques
US20170128434A1 (en) Novel estrogen receptor ligands
US20090176841A1 (en) Novel 6-5 system bicyclic heterocyclic derivative and its pharmaceutical utility

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees